Theorem Clinical Research

Drug Sponsors

Almirall reorganizes in Europe, cuts 250 positions

Friday, December 6, 2013 12:57 PM

Pharmaceutical company Almirall has reorganized in Europe to optimize its portfolio potential. Pharmaceutical markets in Europe, particularly in Spain, have been affected in recent years by economically driven decisions made by various countries’ health authorities that have negatively affected the growth of those markets and the introduction and uptake of new products. 

More... »

Fred Hutchinson, Memorial Sloan-Kettering team up to launch Juno Therapeutics

Thursday, December 5, 2013 10:49 AM

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children’s Research Institute, have joined forces to launch Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

More... »

Cord Blood Registry, U.S. Women's Health Alliance partner

Wednesday, December 4, 2013 01:02 PM

Cord Blood Registry (CBR), a newborn stem cell company, and the U.S. Women's Health Alliance have partnered on a nationwide patient education and quality initiative to ensure all expectant parents understand their options regarding umbilical cord stem cell collection and possibly improve medical outcomes for their families.

More... »

Eisai restructures, cuts 180 jobs

Monday, December 2, 2013 01:05 PM

Eisai’s R&D organization, Eisai Product Creation Systems (EPCS), is restructuring and will cut 180 jobs.

More... »

HeartWare International acquires CircuLite

Monday, December 2, 2013 12:59 PM

HeartWare International, an innovator of less invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, has acquired CircuLite, developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent.

More... »

SillaJen to acquire Jennerex

Wednesday, November 27, 2013 02:00 PM

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

More... »

Nicox acquires Eupharmed

Wednesday, November 27, 2013 11:48 AM

Nicox, an international pharmaceutical company focused on the ophthalmic market, has acquired Eupharmed, a privately-held Italian ophthalmic company, for $4.8 million in newly issued Nicox shares, plus milestones of up to $3.3 million. The acquisition provides Nicox with an established sales and marketing platform in Italy and a broad portfolio of eye care products. Eupharmed had sales of $4.9 million in 2012 and is expected to see full-year sales of approximately $5.3 million in 2013.

More... »

Flagship VentureLabs launches Seres Health

Friday, November 22, 2013 12:48 PM

Flagship VentureLabs has launched Seres Health after two years of development in stealth mode and $10.5 million in Series A financing during that period from Flagship Ventures and other investors. Seres Health is a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on novel scientific findings related to the human microbiome. Seres has developed a unique understanding of the functional nature of the human microbiome and has used this knowledge to pioneer Ecobiotic therapeutics, the first class of agents that addresses the ecological nature of the microbiome. 

More... »

Amicus Therapeutics acquires Callidus Biopharma, reduces workforce 14%

Friday, November 22, 2013 12:47 PM

Amicus Therapeutics, a biopharmaceutical company focused on therapies for rare and orphan diseases, has acquired Callidus Biopharma and announced restructuring of its biologics business strategy.

More... »

Cardiome acquires Correvio

Wednesday, November 20, 2013 12:52 PM

Cardiome Pharma has completed the acquisition of Correvio, a privately-held pharmaceutical company in Geneva, to accelerate Cardiome's launch of BRINAVESS (vernakalant IV) and reduce BRINAVESS build out costs.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs